New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2013
20:25 EDTTXT, TXT, STJ, STJ, NTRS, NTRS, MAT, MAT, GWW, GWW, BK, BK, PNC, PNC, ABT, ABT, USB, USB, BAC, BACNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Bank of America (BAC), consensus 25c; U.S. Bancorp (USB), consensus 76c; Abbott Laboratories (ABT), consensus 44c; PNC Financial Services (PNC), consensus $1.63; BNY Mellon (BK), consensus 57c; W.W. Grainger (GWW) , consensus $2.96; Mattel (MAT), consensus 32c; Northern Trust (NTRS), consensus 83c; St. Jude Medical (STJ), consensus 94c; Textron (TXT), consensus 38c.
News For BAC;USB;ABT;PNC;BK;GWW;MAT;NTRS;STJ;TXT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 23, 2015
09:03 EDTABTFiserv says Abbott employee credit union expands partnership
Subscribe for More Information
06:03 EDTGWWU.S. Multi-Industry sector downgraded to Neutral at Barclays
Barclays downgraded the U.S. Multi-Industry space to Neutral from Overweight saying rising headwinds could limit share upside to mid-single-digit levels in 2015, with only slight improvement in 2016. The firm believes the credit cycle is peaking and views the U.S. Dollar strength along with lower oil prices as headwinds. Concurrent with sector rating change, Barclays downgraded Dover (DOV), Grainger (GWW), Xylem (XYL) and WESCO (WCC) to Equal Weight from Overweight. It also upgraded Tyco (TYC) to Overweight from Equal Weight and Lennox (LII) to Equal Weight from Underweight, calling both defensive names in the space. The firm is also "comfortable" owning General Electric (GE), Honeywell (HON), Sensata (ST) and HD Supply (HDS) at current levels. It prefers waiting for pullbacks to buy shares of 3M (MMM).
05:47 EDTGWWGrainger downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Grainger to Equal Weight after cutting its rating on the U.S. Industrial space to Neutral from Positive. The firm believes cycle risks could limit stock returns to mid-single-digit levels in 2015, with only a slight pickup in 2016. It dropped its price target for Grainger shares to $237 from $254.
March 20, 2015
10:36 EDTBACBank of America changes bylaws to allow some investors to nominate directors
Subscribe for More Information
05:57 EDTBACBank of America faces pressure to defend structure, Financial Times reports
Bank of America will have to defend its current structure at its annual meeting in May after the SEC allowed a small shareholder the right to challenge the board on a break-up, reports the Financial Times. Bank of America's board could be under pressure to appoint a committee to examine a plan for divesting all non-core banking businesses if a proposal from Barlett Naylor of Public Citizen is adopted. Reference Link
March 19, 2015
16:02 EDTBKBNY Mellon settles FX-related actions
Subscribe for More Information
11:53 EDTUSB, BACU.S. banks face headwinds in unloading oil loans, WSJ says
Subscribe for More Information
11:32 EDTBKBNY Mellon set to pay $700M to settle forex allegations, WSJ says
Subscribe for More Information
11:16 EDTBKBNY Mellon close to deal to resolve forex litigation for $700M, Reuters reports
Subscribe for More Information
06:30 EDTBACSEC says BofA must put investment bank spinoff to shareholder vote, Reuters says
The SEC has told Bank of America that it must allow shareholders to vote on whether the company will attempt to spin off its investment bank unit, reports Reuters, citing a decision by the Securities and Exchange Commission. A bank spokesperson said the company "will respond to the proposal in our proxy statement." Reference Link
March 18, 2015
10:00 EDTSTJOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:10 EDTBACPlatts to hold a forum
11th Annual Steel Markets North America is being held in Chicago on March 17-18.
05:39 EDTSTJSt. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.
March 17, 2015
08:34 EDTPNCPNC Financial reinstated with a Market Perform at Raymond James
08:34 EDTBACBank of America reinstated with an Outperform at Raymond James
Subscribe for More Information
March 16, 2015
13:16 EDTSTJAnalysts upbeat on results of Edwards' Sapien 3 data
The shares of Edwards Lifesciences (EW) are rising after the company released data on its Sapien 3 transcathter aortic valve over the weekend. In notes to investors today, a number of analysts were upbeat on the data. BACKGROUND: Edwards yesterday announced that high- and intermediate-risk patients treated with Sapien 3 demonstrated lower mortality rates than patients treated with previous transcathter aortic valves, or TAVR, made by the company. The patients also had excellent clinical outcomes in the other primary endpoints of stroke and paravalvular regurgitation, the company stated. Meanwhile, a five year study of patients treated with the first generation SAPIEN device showed that the patients had equivalent outcomes to traditional open-heart surgery, and no structural valve deterioration requiring intervention, the company stated. ANALYST REACTION: Edwards' Sapien 3 data was impressive, as the device showed one of the lowest stroke and mortality rates of any major TAVR study so far, Bernstein analyst Derrick Sung wrote in a note to investors earlier today. Data presented by Edwards and other companies at the American College of Cardiology, or ACC, conference this weekend caused investors and the medical community to become more optimistic about the potential for TAVR devices to replace surgical valves, Sung stated. The analyst wrote that he continues to believe that investors are underestimating the potential size of the TAVR market. Also upbeat on Edwards' data was Wells Fargo, which wrote that the data exceeded high expectations and could pressure the FDA to approve Sapien 3 for intermediate risk patients earlier than Edwards' guidance of late 2016. WHAT'S NOTABLE: Analysts were also upbeat on data reported by other companies at the ACC conference. Medtronic's (MDT) data suggested that its CoreValve Evolut-R product may be as effective as Edwards' Sapien 3, Bernstein's Sung stated. The FDA appears to have allowed Boston Scientific's (BSX) left atrial appendage closure, Watchman, to be provided to more patients than expected, research firm Stifel believes. Meanwhile, St. Jude's (STJ) CardioMEMS device yielded "impressive" mortality data, the firm added. Stifel kept Buy ratings on both Medtronic and St. Jude. PRICE ACTION: In early afternoon trading, Edwards Lifesciences climbed 9% to $147.64, Boston Scientific advanced 4% to $17.27, St. Jude added 2% to $67.55, and Medtronic rose 1.3% to $77.50.
10:22 EDTBACBank of America February default rate 2.98% vs. 2.93% last month
Reports February delinquency rate 1.86% vs. 1.83% last month.
08:05 EDTSTJSt. Jude Medical data 'impressive,' says BMO Capital
Subscribe for More Information
March 15, 2015
14:16 EDTABTAbbott announces 'favorable' data from MitraClip study
Subscribe for More Information
12:47 EDTSTJSt. Jude Medical announces new data analysis from CHAMPION trial
St. Jude Medical announced a new data analysis from the CHAMPION trial showing that heart failure, HF, patients with reduced ejection fraction on optimal doses of guideline directed medical therapy, GDMT, managed by pulmonary artery, PA, pressure monitoring with the CardioMEMS HF System had a 57% reduction in mortality and a 43% reduction in HF hospitalizations compared with patients on GDMT managed by the standard of care, SOC. These data show a strong improvement for patients managed by optimal GDMT and the CardioMEMS HF System in both mortality and hospitalizations over currently defined best practices.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use